Shield Therapeutics PLC (LSE:STX, FRA:1JS)'s (LON:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the firm hinges on the success of their US launch of commercialising Accrufer.
This treatment is for iron deficiency or anaemia and as Savin explains Shield owns the product, which means they would be taking all the profit but, most importantly, controlling the process.
He says the market is large with 10mln oral prescriptions a year. And Accrufer offers excellent tolerability and efficacy compared to other oral iron products.